Steve Schonfeld’s Mineralys Therapeutics MLYS Stock Holding History

Steve Schonfeld’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Sell	95,242 -82,343	-46%	-$2.26M	0.01%	932
2026 Q1	$4.81M	Buy	177,585 +127,764	+256%	+$3.75M	0.03%	505
2025 Q4	$1.81M	Buy	49,821 +35,203	+241%	+$1.41M	0.01%	909
2025 Q3	$554K	Sell	14,618 -238,581	-94%	-$5.16M	﹤0.01%	1647
2025 Q2	$3.43M	Buy	253,199 +35,737	+16%	+$518K	0.02%	719
2025 Q1	$3.45M	Buy	+217,462	New	+$2.5M	0.02%	672
2023 Q4	–	Sell	-192,362	Closed	-$1.83M	–	2081
2023 Q3	$1.83M	Buy	192,362 +75,248	+64%	+$981K	0.01%	856
2023 Q2	$2M	Buy	117,114 +28,266	+32%	+$422K	0.02%	757
2023 Q1	$1.39M	Buy	+88,848	New	+$1.5M	0.01%	811

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steve Schonfeld's MLYS Position: Q2 2026 in Review

Steve Schonfeld reduced its Mineralys Therapeutics (MLYS) stake by 46% in Q2 2026, selling an estimated $2.26M and leaving 95,242 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #932.

Steve Schonfeld first reported a position in MLYS in Q1 2023 and has held it in 9 quarters since. The position peaked at $4.81M in Q1 2026. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Steve Schonfeld held 95,242 shares of Mineralys Therapeutics worth $2.57M as of Q2 2026.
Steve Schonfeld sold 82,343 Mineralys Therapeutics shares in Q2 2026, an estimated $2.26M.
Mineralys Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #932 holding.
Steve Schonfeld first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 9 quarters since.
Steve Schonfeld's Mineralys Therapeutics position peaked at $4.81M in Q1 2026.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.